54 filings
8-K
GRI
GRI Bio Inc
1 Apr 24
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
9:13am
8-K
GRI
GRI Bio Inc
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
8-K
GRI
GRI Bio Inc
30 Jan 24
GRI Bio Announces Reverse Stock Split
8:12am
8-K
GRI
GRI Bio Inc
19 Jan 24
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
GRI
GRI Bio Inc
16 Jan 24
Regulation FD Disclosure
8:45am
8-K
kdz17z yh
5 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:05pm
8-K
ik05z28lc5e
5 Dec 23
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway
9:07am
8-K
g1e qk0g3xh3r
27 Nov 23
Clinical development plan leveraging 505(b)(2) regulatory pathway
8:38am
8-K
e328rf5t70m33blb0vab
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
8-K
nr5g2 8zhdv59
15 Nov 23
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024
8:07am
8-K
r0ni25m4g93q5fpglyj7
1 Nov 23
Regulation FD Disclosure
8:45am
8-K
1pooewfz
25 Aug 23
Regulation FD Disclosure
4:42pm
8-K
qkek y626s
23 Aug 23
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
9:07am
8-K
zq7 xvye78
14 Aug 23
On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023
8:06am
8-K
z50f5z d7
7 Jul 23
Submission of Matters to a Vote of Security Holders
4:03pm
8-K/A
8avhe bn3fzaco
6 Jul 23
Financial Statements and Exhibits
4:28pm
8-K/A
60l4qfp7
26 May 23
Financial Statements and Exhibits
4:15pm
8-K
4lccgs1k qvtk9l
27 Apr 23
Other Events
9:12am
8-K
6f41 qc3o1
27 Apr 23
Regulation FD Disclosure
8:40am
8-K
bmmn ne1hc42z
21 Apr 23
Investment proceeds expected to fund planned operations of the combined company into mid-2024
5:14pm